News | October 11, 2023
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
The inspection was a cGMP Inspection and had ended with NIL observations
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Subscribe To Our Newsletter & Stay Updated
